Share Name Share Symbol Market Type Share ISIN Share Description
Vernalis LSE:VER London Ordinary Share GB00B3Y5L754 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.375p -1.97% 18.625p 18.25p 19.00p 18.25p 18.25p 18.25p 293,096 16:35:01
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 12.0 -15.3 -3.2 - 98.05

Vernalis Share Discussion Threads

Showing 3326 to 3349 of 3350 messages
Chat Pages: 134  133  132  131  130  129  128  127  126  125  124  123  Older
DateSubjectAuthorDiscuss
18/7/2017
08:42
Plenty of room to bounce higher, just don't seem to have the natural buyers....
chrisdgb
18/7/2017
08:25
CCP-08 approval statement is due in August. I would hope for better news on both 07 and 08 by the September results or the whole franchise could be in trouble.
fhmktg
18/7/2017
08:24
makes a change
bountyhunter
18/7/2017
07:54
PILE in NOW
hvs
14/7/2017
10:46
Agreed, we could do with a dose of good news for a change......
chrisdgb
14/7/2017
08:14
The run rate at June 30th for Tuzistra was touted as an indicator for future potential in the interim report.So the pre results update for the year to end June is very important, plus updates on the later CP series, plus Moxatag 'news'I had expected this during the last week.Hope this delay does not suggest bad news coming!
fhmktg
12/7/2017
14:22
When there is blood on the streets and all that..........
chrisdgb
12/7/2017
13:49
...at least I have some oxb to balance out the horrendous situation here, certainly in the running for my most disappointing share, ...maybe one day things will change!
bountyhunter
12/7/2017
13:39
Couldn't be more despondent.
fhmktg
12/7/2017
13:18
Pretty low volumes but a few buys possibly hoping for an imminent update..?
chrisdgb
26/6/2017
07:39
Around 7th July for the year end trading update.Poor communication so far, of what is happening with the FDA and Moxatag.With another review of CP08 due soon, let's hope we get a clear idea of strategy for the coming years!Looking like a turkey at the moment.
fhmktg
23/6/2017
12:06
Next news anyone...???
chrisdgb
08/6/2017
07:22
absolutely
bountyhunter
07/6/2017
16:06
Lets hope not. Management buyouts are a nightmare for investors. 10 cents on the dollar if you're lucky.
bantam175
07/6/2017
08:17
Nothing worth having until the Tris products have shown their metal....or not.A management buy out could be a possibility?
fhmktg
07/6/2017
07:46
Any chance of a takeover..??
chrisdgb
02/6/2017
15:17
agreed, seems to be on a stairway to hell right now, we certainly are in dire need of some positive news!
bountyhunter
02/6/2017
15:00
Could really do with some kind of upbeat statement from the board. Maybe there's nothing to be upbeat about? Come on guys.
bantam175
18/5/2017
13:37
This is awful................
chrisdgb
26/4/2017
23:44
@jneubig What is your source for this claim? Tris has been audited regularly by the FDA with no prior serious issues.
romeike
22/4/2017
06:52
Not a pharmacokinetic or formulation issue? Did they mention labeling? If it was something simple then why not say so. Was it a safety issue? Why not say if it was or was not? Investors have the right to be kept fully informed. The FDA are serious people-don't issue complete response letters wily-nily. Are other products with similar profiles going to be similarly challenged? Can cost millions and take years to challenge the FDA or get them round to your way of thinking. RNS too vague to be sure this is not finished imo, and if Tuzistra sales don't start taking off Ver could be in in deep trouble imo. Also lack of news on Moxtag a concern imo for investors. Having started with huge cash pile this could easily be frittered away given costs of running an expensive mgmt team, sales force, regulatory hurdles etc. Without serious good news on sales, deals, approvals etc today's share price could look expensive before the year is out. imo
cumnor
22/4/2017
01:46
Vernalis is not getting product approval anytime soon. The 'delay' is due to their development partner and contract manufacturer Tris Pharma having an unsuccessful FDA inspection. This has put all development data into question along with the production of the registration batches. Tris has been told by the FDA that they are moving forward with a warning letter, which will put all product approvals on Hold from that facility for at least a year. Vernalis is screwed - should have picked a better business partner than Tris PHarma. Sell now....
jneubig
21/4/2017
09:10
Let's wait for a fuller explanation of what the FDA want.If it's just a labelling detail, then just a short delay. If they are after further data which requires testing then VER could miss the tight time schedule to be ready for next season.We should get more clarity once the FDA letter has been studied.
fhmktg
21/4/2017
08:39
'Delay' seems over reaction, not 'failed'........
chrisdgb
Chat Pages: 134  133  132  131  130  129  128  127  126  125  124  123  Older
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:33 V: D:20170724 18:51:11